Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation (CIC).

Help employers find you! Check out all the jobs and post your resume.

Back to news